MX2018014443A - 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas. - Google Patents
3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas.Info
- Publication number
- MX2018014443A MX2018014443A MX2018014443A MX2018014443A MX2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A MX 2018014443 A MX2018014443 A MX 2018014443A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- dihydropyridazine
- diphenyl
- oxo
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención cubre compuestos de 3-oxo-2,6-difenil-2,3-di hidropiridazin-4-carboxamida de fórmula general (I): (ver Fórmula) en la cual R1, R2, R3, R4, R5 y R6 son según lo definido en la presente invención, métodos para preparar dichos compuestos, compuestos intermedios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y la utilización de dichos compuestos para manufacturar composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular del cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización aberrante del AHR, como un agente único o en combinación con otros ingredientes activos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016083308 | 2016-05-25 | ||
CN2017074408 | 2017-02-22 | ||
PCT/EP2017/062355 WO2017202816A1 (en) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014443A true MX2018014443A (es) | 2019-04-15 |
Family
ID=58745251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014443A MX2018014443A (es) | 2016-05-25 | 2017-05-23 | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas. |
Country Status (27)
Country | Link |
---|---|
US (1) | US11040035B2 (es) |
EP (1) | EP3464248B1 (es) |
JP (1) | JP6964096B2 (es) |
KR (1) | KR20190009369A (es) |
CN (1) | CN109863140B (es) |
AU (1) | AU2017269870A1 (es) |
BR (1) | BR112018074185A2 (es) |
CA (1) | CA3025227A1 (es) |
CL (1) | CL2018003345A1 (es) |
CO (1) | CO2018012654A2 (es) |
CR (1) | CR20180556A (es) |
CU (1) | CU20180143A7 (es) |
DO (1) | DOP2018000256A (es) |
EA (1) | EA201892666A1 (es) |
EC (1) | ECSP18087725A (es) |
IL (1) | IL263046A (es) |
MA (1) | MA45087A (es) |
MX (1) | MX2018014443A (es) |
NI (1) | NI201800124A (es) |
PE (1) | PE20190509A1 (es) |
PH (1) | PH12018502472A1 (es) |
SG (1) | SG11201810366WA (es) |
SV (1) | SV2018005787A (es) |
TN (1) | TN2018000392A1 (es) |
TW (1) | TW201742859A (es) |
UY (1) | UY37256A (es) |
WO (1) | WO2017202816A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
JOP20190193A1 (ar) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
EP3713931A1 (en) * | 2017-11-21 | 2020-09-30 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
WO2019101647A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
PT3580211T (pt) * | 2017-11-21 | 2021-02-01 | Deutsches Krebsforsch | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro |
EP3713922A1 (en) * | 2017-11-21 | 2020-09-30 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
CA3110402A1 (en) | 2018-08-24 | 2020-02-27 | Jaguahr Therapeutics Pte Ltd | Tetrahydropyridopyrimidine derivatives as ahr modulators |
KR20210053911A (ko) | 2018-08-31 | 2021-05-12 | 재규어 테라퓨틱스 피티이 리미티드 | Ahr 조절제로서의 헤테로사이클릭 화합물 |
CN109771437B (zh) * | 2019-03-28 | 2023-03-17 | 西安交通大学医学院第一附属医院 | 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用 |
EP3715471A1 (en) * | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
WO2021020362A1 (ja) * | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
KR20220128622A (ko) * | 2019-12-16 | 2022-09-21 | 바이엘 악티엔게젤샤프트 | Ahr-억제제 및 pd1-억제제 항체의 조합물 및 암 치료에서의 그의 용도 |
CN115190799A (zh) | 2020-01-10 | 2022-10-14 | 医肯纳肿瘤学公司 | Ahr抑制剂及其用途 |
CN115244048A (zh) | 2020-02-26 | 2022-10-25 | 捷豹治疗有限公司 | 可用于调节AhR信号传导的吡啶并嘧啶衍生物 |
MX2022011826A (es) * | 2020-03-27 | 2022-10-18 | Dong A St Co Ltd | Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo. |
US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
CN114685426A (zh) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | 磺酰胺类抑制剂及其制备方法和应用 |
TW202320777A (zh) * | 2021-09-14 | 2023-06-01 | 中國大陸商元啟(蘇州)生物製藥股份有限公司 | 芳基烴受體調節劑及其用於治療疾病及病症之用途 |
WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
AU756275B2 (en) * | 1998-08-14 | 2003-01-09 | Nihon Nohyaku Co., Ltd. | Pyridazinone derivatives |
HU228961B1 (en) * | 2000-09-18 | 2013-07-29 | Eisai R & D Man Co | Triazinones and their use as active ingredients of pharmaceutical compositions |
FR2847253B1 (fr) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
FR2847235B1 (fr) | 2002-11-20 | 2005-07-08 | Essilor Int | Emballage de protection et de calage pour objets a contour circulaire |
AR057986A1 (es) * | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | Compuesto heterociclico y su uso farmaceutico |
EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
JP6047092B2 (ja) | 2010-07-27 | 2016-12-21 | トラスティーズ オブ ボストン ユニバーシティ | 新規癌治療法としてのアリール炭化水素受容体(AhR)改変物質 |
US20170173008A1 (en) | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
-
2017
- 2017-05-23 JP JP2018561224A patent/JP6964096B2/ja active Active
- 2017-05-23 TN TNP/2018/000392A patent/TN2018000392A1/en unknown
- 2017-05-23 BR BR112018074185-0A patent/BR112018074185A2/pt not_active IP Right Cessation
- 2017-05-23 CA CA3025227A patent/CA3025227A1/en active Pending
- 2017-05-23 CN CN201780046149.5A patent/CN109863140B/zh active Active
- 2017-05-23 SG SG11201810366WA patent/SG11201810366WA/en unknown
- 2017-05-23 CR CR20180556A patent/CR20180556A/es unknown
- 2017-05-23 EA EA201892666A patent/EA201892666A1/ru unknown
- 2017-05-23 KR KR1020187037050A patent/KR20190009369A/ko not_active Application Discontinuation
- 2017-05-23 MA MA045087A patent/MA45087A/fr unknown
- 2017-05-23 CU CU2018000143A patent/CU20180143A7/es unknown
- 2017-05-23 WO PCT/EP2017/062355 patent/WO2017202816A1/en unknown
- 2017-05-23 US US16/303,539 patent/US11040035B2/en active Active
- 2017-05-23 PE PE2018003109A patent/PE20190509A1/es unknown
- 2017-05-23 EP EP17724833.3A patent/EP3464248B1/en active Active
- 2017-05-23 AU AU2017269870A patent/AU2017269870A1/en not_active Abandoned
- 2017-05-23 MX MX2018014443A patent/MX2018014443A/es unknown
- 2017-05-24 UY UY0001037256A patent/UY37256A/es not_active Application Discontinuation
- 2017-05-25 TW TW106117299A patent/TW201742859A/zh unknown
-
2018
- 2018-11-15 IL IL263046A patent/IL263046A/en unknown
- 2018-11-23 DO DO2018000256A patent/DOP2018000256A/es unknown
- 2018-11-23 SV SV2018005787A patent/SV2018005787A/es unknown
- 2018-11-23 EC ECSENADI201887725A patent/ECSP18087725A/es unknown
- 2018-11-23 PH PH12018502472A patent/PH12018502472A1/en unknown
- 2018-11-23 NI NI201800124A patent/NI201800124A/es unknown
- 2018-11-23 CL CL2018003345A patent/CL2018003345A1/es unknown
- 2018-11-23 CO CONC2018/0012654A patent/CO2018012654A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112018074185A2 (pt) | 2019-03-06 |
CL2018003345A1 (es) | 2019-03-15 |
DOP2018000256A (es) | 2019-02-15 |
CN109863140B (zh) | 2023-02-21 |
SV2018005787A (es) | 2019-02-07 |
TW201742859A (zh) | 2017-12-16 |
TN2018000392A1 (en) | 2020-06-15 |
KR20190009369A (ko) | 2019-01-28 |
IL263046A (en) | 2018-12-31 |
EP3464248A1 (en) | 2019-04-10 |
SG11201810366WA (en) | 2018-12-28 |
AU2017269870A1 (en) | 2018-12-06 |
ECSP18087725A (es) | 2018-11-30 |
EA201892666A1 (ru) | 2019-08-30 |
CR20180556A (es) | 2019-04-23 |
PE20190509A1 (es) | 2019-04-10 |
PH12018502472A1 (en) | 2019-09-23 |
NI201800124A (es) | 2019-04-29 |
US20200237757A1 (en) | 2020-07-30 |
CA3025227A1 (en) | 2017-11-30 |
CO2018012654A2 (es) | 2018-12-14 |
UY37256A (es) | 2018-01-02 |
CU20180143A7 (es) | 2019-07-04 |
JP2019516744A (ja) | 2019-06-20 |
MA45087A (fr) | 2021-05-26 |
US11040035B2 (en) | 2021-06-22 |
WO2017202816A1 (en) | 2017-11-30 |
CN109863140A (zh) | 2019-06-07 |
EP3464248B1 (en) | 2021-09-08 |
JP6964096B2 (ja) | 2021-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502472A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
PH12019501846A1 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
PH12019501034A1 (en) | New anthelmintic quinoline-3-carboxamide derivatives | |
PH12018550173A1 (en) | Pyrazolopyrimidine derivatives | |
PH12020500257A1 (en) | Quinoline derivatives for treating infections with helminths | |
PH12019502851A1 (en) | New azaquinoline derivatives | |
WO2018077944A3 (en) | 4,5-annulated 1,2,4-triazolones | |
MX2022006466A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune. | |
PH12020551891A1 (en) | New quinoline derivatives | |
MX2019012803A (es) | Nuevos derivados de pirazol biciclicos. | |
WO2017198341A8 (en) | MACROCYCLIC INDOLE DERIVATIVES | |
MX2022001803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas. | |
MX2020001404A (es) | Dihidrooxadiazinonas. | |
PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
EA201991835A1 (ru) | 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования |